ENVIE Co-ordination action on indoor air quality and health effects; WP3 Final report – Characterisation of spaces and source

Human exposure to environmental pollutants occurs via various pathways. For many pollutants, especially the volatile ones, air exposure is the dominant pathway. Exposure via air occurs both outdoors and indoors, with diverse types of indoor spaces playing a role, e.g., home, workplace, and passenger cabins of means of transportation. In average people spend over 90% of their time indoors, that percentage being particularly high for some specific groups as new-born, elderly, disabled or sick people. The global exposure to air contaminants is therefore drastically determined by indoor conditions. It is now well established that indoor air pollution contributes significantly to the global burden of disease of the population. For a majority of indoor air contaminants, particularly in the presence of common indoor sources, however, indoor concentrations usually exceed outdoor concentrations, for some pollutants even with an indoor/outdoor ratio of 10 or 20. Emissions are identified, accordingly to the EnVIE approach and grouped into four categories: building materials and related sources, including dampness and moulds; ventilation, natural and mechanical, including, or not, heating, cooling and humidification/ dehumidification; consumer products, furnishing, cleaning and household products; and occupant activities. Emission of chemical substances from construction materials and products in buildings to the indoor air have been reported and reviewed for a wide range of substances, including those formed during secondary reactions, causing complaints of irritation and odour. During the last two decades there has been increasing advances in construction technology that have caused a much greater use of synthetic building materials. Whilst these improvements have led to more comfortable buildings, they also provide indoor environments with contaminants in higher concentrations than are found outside. Wood and cork are now frequently used as a building product for floor coverings, because the material is often regarded as “natural” and “healthy”. However, industrial products, even based on natural raw materials, may contain a number of artificial ingredients and the chemical emissions will strongly depend on the type of additives and the manufacturing process. Modern interior paints are usually based on a polymeric binder. In order to fulfil requirements on e.g., durability, paint contains various functional chemicals. Water-borne paints usually also contains small amounts of approved biocides. Polymeric binders with a very low content of residual monomers have been developed for paint. Besides the release of substances to the indoor air due to primary emission, damp building materials may give rise to volatile substances formed during secondary reactions. Semi-volatile organic compounds (SVOCs) are now receiving much more attention than heretofore. The HVAC (Heating, Ventilation and Air Conditioning) systems as providers, among others, of services of cleaning and dilution of pollutants in the indoor air are also recognized as potential pollution sources. Several studies have shown that the prevalence of SBS symptoms is often higher in air conditioned buildings than in buildings with natural ventilation. 8 The outdoor air introduced indoors through either ventilation systems or natural means is also an important and not always controllable source for the intake of some outdoor pollutants. Outdoor air used for ventilation may also be source of pollution containing particulate matter, particulates of biological origin (microorganisms, pollen, etc.) and various gases like NOx and O building structures which is a driving force for the airflows which will transport to indoors water vapour and gaseous or particulate contaminants. Volatile organic compounds are emitted from a wide variety of household and consumer products with emission rates that are strongly dependent on the type of application and are distributed over several orders of magnitude. A number of product classes are identified and information on ingredients and available data on emissions from individual products are presented. Human activities and the associated use of products encompass a wide range of indoor sources involving release of inorganic gases, particles and organic compounds as a consequence of the activity. For some releases such as with air fresheners the release is a necessary part of the activity to achieve the intended effect whereas for others, such as the release of combustion fumes from a gas appliance, the purpose of the action (in this case generation of heat) is different from the emission. Combustion processes are an important source of a range of air pollutants as carbon monoxide, nitrogen dioxide, sulphur dioxide, particulates and associated inorganic and organic chemicals, organic vapours e.g. formaldehyde, acetaldehyde, and benzene. Sources of these are present in both ambient and indoor environments. The concentrations present in the ambient air provide a baseline for the level of pollutant found indoors as this air enters indoors by processes of infiltration and ventilation. However, the concentration indoors will be modified by processes of sorption to surfaces and chemical reaction depending on the chemical and physical properties of the pollutant and internal surfaces. People themselves are a source of emissions of chemicals and gases, notably CO range of organic compounds that are referred to as body odours. The removal of such body odours is a prime objective of ventilation in order to achieve a satisfactory indoor environment. WP3 aims at to characterize spaces and sources in order to understand where and how to act to guarantee good IAQ. From the two strategies for good IAQ, source control and ventilation, the precautionary principle suggests that first priority shall be given to source control, avoiding, mitigating or simply managing sources of emissions. An overview of all policies on IAQ or related to IAQ, existing or in preparation, directly related to indoor air sources, but also covering outdoor air and industrial emissions, which could affect indirectly IAQ is made. Considering the presented it could be concluded that IAQ is yet poorly regulated at EU level, and in view of that some recommendations are made. The recommendations on policies have taken into account the existing related to IAQ policies such as new EU policies on chemicals (REACH; 2006/121/EC), consumer products (GPSD; 2001/95/EC), construction products (CPD; 89/106/EC) and energy performance of buildings (EPBD; 2002/91/EC) all refer to IAQ issues - suggesting that they could, and probably should, contribute to IAQ policy development and advocate an integrative and comprehensive policy approach centred

Estudo de emissões de COVs por materiais usados em interiores de edifícios

Dissertação de Doutoramento em Química apresentada à Faculdade de Ciências da Universidade do PortoA qualidade do ar interior em ambientes residenciais e de trabalho não industrial tem vindo a ser objecto de atenção crescente por parte da comunidade científica e do público em geral. O número de casos de queixas de mal-estar (síndroma dos edifícios doentes), de alergias e outras doenças relacionáveis com os edifícios tem aumentado, levando à necessidade de mais estudos, e mais aprofundados, sobre o ambiente interior e o seu impacto no homem. Uma das estratégias apontadas para melhorar a qualidade do ambiente interior dos edifícios, designada por controlo na fonte, passa pelo recurso a materiais menos poluentes e a sistemas de ventilação optimizados.O presente trabalho, provavelmente o primeiro realizado em Portugal neste tópico, teve como primeiro objectivo a implementação de toda uma metodologia para o estudo das emissões de compostos orgânicos voláteis (COVs) por materiais de revestimento de interiores. Tratou-se de um trabalho interdisciplinar que englobou contribuições das áreas da Química e da Engenharia Mecânica. A escolha de materiais de construção de baixa emissão implica a prévia caracterização do seu potencial poluidor. Porém, a caracterização de emissões dos materiais de construção de um edifício in situ é extremamente difícil, devido ao grande número de parâmetros que influenciam as concentrações dos poluentes do ar, tais como, temperatura, humidade relativa, taxa de ventilação e velocidade do ar à superfície do material. Por isso, o estudo das emissões de COVs passa, em geral, pela utilização de câmaras de teste. As amostras geradas na câmara de teste foram recolhidas por adsorção, em tubos contendo Tenax TA, desadsorvidas termicamente e identificadas/quantificadas por cromatografia gasosa com detectores selectivo de massa/ionização de chama. Apenas os aldeídos e cetonas de baixa massa molecular foram recolhidos em cartuchos de sílica recoberta por dinitrofenilhidrazina, e analisados por cromatografia líquida de alta eficiência. Foi dada uma impor ..

Impact of Cognitive Behavioral Therapy on Resting Cardiac Parameters and Cortisol in Patients with Post-Traumatic Stress Disorder: A Pilot Randomized Clinical Trial

Post-Traumatic Stress Disorder (PTSD) has been associated with changes in psychophysiological and neuroendocrinal parameters. Cognitive Behavioral Therapy (CBT) is considered the treatment of choice for PTSD and is able to regularize altered neurobiological parameters; however, little is known about its effects on these parameters when measured during the therapeutic process. This pilot study aimed to evaluate the impact of CBT on cortisol and cardiac parameters measured at rest during the treatment of PTSD with comorbid major depression. 14 patients were randomized to four months of CBT or a waiting list. As expected, the experimental group had a greater reduction in PTSD symptoms and a large effect size. There was a reduction in the low frequency component of heart rate variability, which achieved borderline statistical significance and a large effect size. Salivary cortisol tended to track the progress of therapy, rising in the period of exposure and decreasing by the end of treatment. Despite the small sample size, this study opens the way for further research into the impact of CBT on the different biological markers of PTSD during the therapeutic process. This can hopefully help to optimize and personalize therapeutic studies while providing clues about modifications in bio behavioral pathological manifestations

Nanopharmaceutics: Part II - Production scales and clinically compliant production methods

Due the implementation of nanotechnologies in the pharmaceutical industry over the last few decades, new type of cutting-edge formulationsnanopharmaceuticshave been proposed. These comprise pharmaceutical products at the nanoscale, developed from different types of materials with the purpose to, e.g., overcome solubility problems of poorly water-soluble drugs, the pharmacokinetic and pharmacodynamic profiles of known drugs but also of new biomolecules, to modify the release profile of loaded compounds, or to decrease the risk of toxicity by providing site-specific delivery reducing the systemic distribution and thus adverse side effects. To succeed with the development of a nanopharmaceutical formulation, it is first necessary to analyze the type of drug which is to be encapsulated, select the type matrix to load it (e.g., polymers, lipids, polysaccharides, proteins, metals), followed by the production procedure. Together these elements have to be compatible with the administration route. To be launched onto the market, the selected production method has to be scaled-up, and quality assurance implemented for the product to reach clinical trials, during which in vivo performance is evaluated. Regulatory issues concerning nanopharmaceutics still require expertise for harmonizing legislation and a clear understanding of clinically compliant production methods. The first part of this study addressing Nanopharmaceutics: Part IClinical trials legislation and Good Manufacturing Practices (GMP) of nanotherapeutics in the EU has been published in Pharmaceutics. This second part complements the study with the discussion about the production scales and clinically compliant production methods of nanopharmaceutics.The financial support was received from Portuguese Science and Technology Foundation (FCT/MCT) and from European Funds (PRODER/COMPETE) for the projects M‐ERA‐NET‐0004/2015‐PAIRED and UIDB/04469/2020 (strategic fund), co‐financed by FEDER, under the Partnership Agreement PT2020. Authors thank the support of the project: Nutraceutica come supporto nutrizionale nel paziente oncologico; CUP: B83D18000140007.info:eu-repo/semantics/publishedVersio

Updating the role of matrix metalloproteinases in mineralized tissue and related diseases

Bone development and healing processes involve a complex cascade of biological events requiring well-orchestrated synergism with bone cells, growth factors, and other trophic signaling molecules and cellular structures. Beyond health processes, MMPs play several key roles in the installation of heart and blood vessel related diseases and cancer, ranging from accelerating metastatic cells to ectopic vascular mineralization by smooth muscle cells in complementary manner. The tissue inhibitors of MMPs (TIMPs) have an important role in controlling proteolysis. Paired with the post-transcriptional efficiency of specific miRNAs, they modulate MMP performance. If druggable, these molecules are suggested to be a platform for development of “smart” medications and further clinical trials. Thus, considering the pleiotropic effect of MMPs on mammals, the purpose of this review is to update the role of those multifaceted proteases in mineralized tissues in health, such as bone, and pathophysiological disorders, such as ectopic vascular calcification and cancer

Nanopharmaceutics: Part IClinical trials legislation and Good Manufacturing Practices (GMP) of nanotherapeutics in the EU

The latest advances in pharmaceutical technology are leading to the development of cutting edged approaches to produce what is now known as the “Holy Grail” of medicine—nanopharmaceutics. Over the latest decade, the pharmaceutical industry has made important contributions to the scale up of these new products. To ensure their quality, efficacy, and safety for human use, clinical trials are mandatory. Yet, regulation regarding nanopharmaceuticals is still limited with a set of guidelines being recently released with respect to compliance with quality and safety. For the coming years, updates on regulatory issues about nanopharmaceuticals and their use in clinical settings are expected. The use of nanopharmaceuticals in clinical trials depends on the approval of the production methods and assurance of the quality of the final product by implementation and verification of the good manufacturing practices (GMP). This review addresses the available legislation on nanopharmaceuticals within the European Union (EU), the GMP that should be followed for their production, and the current challenges encountered in clinical trials of these new formulations. The singular properties of nanopharmaceuticals over their bulk counterparts are associated with their size, matrix composition, and surface properties. To understand their relevance, four main clinical trial guidelines, namely, for intravenous iron-based nanopharmaceuticals, liposomal-based nanopharmaceuticals, block copolymer micelle-based nanopharmaceuticals, and related to surface coating requirements, are described here.The financial support was received from Portuguese Science and Technology Foundation (FCT/MCT) and from European Funds (PRODER/COMPETE) for the projects M‐ERA‐NET‐0004/2015‐PAIRED and UIDB/04469/2020 (strategic fund), co‐financed by FEDER, under the Partnership Agreement PT2020. Authors thank the support of the project: Nutraceutica come supporto nutrizionale nel paziente oncologico; CUP: B83D18000140007.info:eu-repo/semantics/publishedVersio

Indoor air quality improvement using nature-based solutions: Design proposals to greener cities

Low indoor air quality is an increasingly important problem due to the spread of urbanization. Because people spend most of their time inside, poor indoor air quality causes serious human health issues, resulting in significant economic losses. In this work, the current state of affairs is presented and analyzed, focusing on the current problems and the available solutions to improve the quality of indoor air, and the use of nature-based solutions. These involve the cultivation of microalgae in closed photobioreactors. In these systems, photosynthetic organisms can capture CO2 and other pollutants generated in indoor environments, which they use to grow and develop biomass. Several possible layouts for the implementation of microalgae-based indoor air cleaning systems are presented, taking into account the systems that are currently available at a commercial scale. A critical analysis of the microalgae indoor purification systems is presented, highlighting their advantages and disadvantages, and suggesting potential improvements and future lines of research and development in the area. (c) 2021 by the authors. Licensee MDPI, Basel, Switzerland